NCT03658213 2021-05-10
LARES
AstraZeneca
Phase 3 Withdrawn
Clinical Trials
6 trialsNCT01240928 2013-08-20
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01240941 2013-08-20
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT01013506 2013-05-23
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT00217659 2013-01-03
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00888082 2010-12-10
PROOF
AstraZeneca
Phase 3 Withdrawn